{"id":"ixekizumab-auto-injector","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Injection site reactions"},{"rate":"15-20","effect":"Upper respiratory tract infections"},{"rate":"1-3","effect":"Candida infections (oral/esophageal)"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1743034","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-17A is a pro-inflammatory cytokine produced by T cells that plays a central role in the pathogenesis of autoimmune and inflammatory conditions. By blocking IL-17A, ixekizumab reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing the inflammatory cascade. This mechanism is particularly effective in conditions driven by Th17 cell-mediated immunity, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.","oneSentence":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:32.533Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Non-radiographic axial spondyloarthritis"}]},"trialDetails":[{"nctId":"NCT05030415","phase":"EARLY_PHASE1","title":"Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2021-08-12","conditions":"Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris","enrollment":9},{"nctId":"NCT01777191","phase":"PHASE3","title":"Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Plaque Psoriasis","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY2439821"],"phase":"phase_3","status":"active","brandName":"Ixekizumab Auto-Injector","genericName":"Ixekizumab Auto-Injector","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}